cheaptrix/billsum-US_congress_and_house huggingface dataset:
GAIN TOOLS Act of 2022

To provide for the designation of biological products as qualified infectious disease products. 1. Short title This Act may be cited as the Generating Antibiotic Incentives Now Through Opening Opportunities to Leverage Science Act of 2022 GAIN TOOLS Act of 2022 2. Expanding qualified infectious disease products to include biological products (a) In general Section 505E of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355f (1) in subsection (c)— (A) in paragraph (2), by striking ; or ; (B) in paragraph (3), by striking the period and inserting ; or (C) by adding at the end the following: (4) an application pursuant to section 351(a) of the Public Health Service Act. ; (2) in subsection (d)(1), by inserting of this Act or section 351(a) of the Public Health Service Act section 505(b) (3) by amending subsection (g) to read as follows: (g) Qualified infectious disease product The term qualified infectious disease product (1) is— (A) an antibacterial or antifungal drug; or (B) a biological product that acts directly on bacteria or fungi or on substances produced by such bacteria or fungi; and (2) is intended to treat a serious or life-threatening infection, including such an infection caused by— (A) an antibacterial or antifungal resistant pathogen, including novel or emerging infectious pathogens; or (B) qualifying pathogens listed by the Secretary under subsection (f). . (b) Priority review Section 524A(a) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 360n–1(a) of this Act, or section 351(a) of the Public Health Service Act, that requires clinical data (other than bioavailability studies) to demonstrate safety or effectiveness

Summary: Generating Antibiotic Incentives Now Through Opening Opportunities to Leverage Science Act of 2022 or the GAIN TOOLS Act of 2022 This bill expands the definition of a qualified infectious disease product (QIDP) to include eligible biological products. Under current law, the first application (or supplement) for a specific product and indication to be designated a QIDP shall receive priority review for market approval by the Food and Drug Administration. Generally, a biological product designated as a QIDP is one that acts on bacteria or fungi and is intended to treat a serious or life-threatening infection. However, a biological product with a QIDP designation shall not receive the market exclusivity extension currently available to drugs that receive the designation.
Preventing Violence Against Female Inmates Act of 2022

To secure the dignity and safety of incarcerated women. 1. Short title This Act may be cited as the Preventing Violence Against Female Inmates Act of 2022 2. Housing prisoners based on sex (a) Federal prisons (1) In general Chapter 303 4051. Bar on housing together prisoners of different sexes (a) Definitions In this section: (1) Biological sex The term biological sex (2) Gender identity The term gender identity (b) Bar The Bureau of Prisons— (1) shall use the biological sex of persons charged with or convicted of offenses against the United States in making determinations regarding housing such persons; and (2) shall not co-locate in detention facilities persons charged with or convicted of offenses against the United States if those persons are not of the same biological sex, unless the Bureau of Prisons co-locates such persons without regard to their purported gender identity. . (2) Technical and conforming amendment The table of sections for chapter 303 4051. Bar on housing together prisoners of different sexes. . (b) State prisons Section 501 of title I of the Omnibus Crime Control and Safe Streets Act of 1968 ( 34 U.S.C. 10152 (h) Bar on housing together prisoners of different sexes (1) Definitions In this subsection, the terms biological sex gender identity (2) Limitation on eligibility for funds Beginning in the first fiscal year beginning after the date of enactment of this subsection, a State may not receive funds under this subpart for a fiscal year if the State does not submit to the Attorney General a certification that the State— (A) prohibits co-locating in detention facilities persons charged with or convicted of offenses under the law of the State if those persons are not of the same biological sex, unless the State co-locates such persons without regard to their purported gender identity; and (B) requires the use of the biological sex of persons charged with or convicted of offenses under the law of the State in making determinations regarding housing such persons. .

Summary: Preventing Violence Against Female Inmates Act of 2022 This bill establishes a framework to prohibit correctional institutions at the federal and state levels from using gender identity to house inmates of one biological sex with inmates of the other biological sex.
A bill to designate the facility of the United States Postal Service located at 3493 Burnet Avenue in Cincinnati, Ohio, as the "John H. Leahr and Herbert M. Heilbrun Post Office".

To designate the facility of the United States Postal Service located at 3493 Burnet Avenue in Cincinnati, Ohio, as the John H. Leahr and Herbert M. Heilbrun Post Office 1. John H. Leahr and Herbert M. Heilbrun Post Office (a) Designation The facility of the United States Postal Service located at 3493 Burnet Avenue in Cincinnati, Ohio, shall be known and designated as the John H. Leahr and Herbert M. Heilbrun Post Office (b) References Any reference in a law, map, regulation, document, paper, or other record of the United States to the facility referred to in subsection (a) shall be deemed to be a reference to the John H. Leahr and Herbert M. Heilbrun Post Office

Summary: Designates the facility of the United States Postal Service located at 3493 Burnet Avenue in Cincinnati, Ohio, as the "John H. Leahr and Herbert M. Heilbrun Post Office."
Justice for ALS Veterans Act of 2022

To amend title 38, United States Code, to extend increased dependency and indemnity compensation paid to surviving spouses of veterans who die from amyotrophic lateral sclerosis, regardless of how long the veterans had such disease prior to death, and for other purposes. 1. Short title This Act may be cited as the Justice for ALS Veterans Act of 2022 2. Extension of increased dependency and indemnity compensation to surviving spouses of veterans who die from amyotrophic lateral sclerosis (a) Extension Section 1311(a)(2) of title 38, United States Code, is amended— (1) by inserting (A) The rate (2) by adding at the end the following new subparagraph: (B) A veteran whom the Secretary determines died from amyotrophic lateral sclerosis shall be treated as a veteran described in subparagraph (A) without regard for how long the veteran had such disease prior to death. . (b) Applicability Subparagraph (B) of section 1311(a)(2) of title 38, United States Code, as added by subsection (a), shall apply to a veteran who dies from amyotrophic lateral sclerosis on or after October 1, 2021.

Summary: Justice for ALS Veterans Act of 2022 This bill extends increased dependency and indemnity compensation to the surviving spouse of a veteran who dies from amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) regardless of how long the veteran had such disease prior to death. Under current law, such compensation is paid for a service-connected disability that was rated totally disabling for a continuous period of at least eight years immediately preceding death.
SERVIS Act

To ensure that the right to vote shall not be impaired due to vaccination status. 1. Short title This Act may be cited as the Securing Enfranchisement and the Rights of Voters regardless of Inoculation Status Act SERVIS Act 2. Right to vote shall not be impaired (a) In general It shall be unlawful for any State or political subdivision, as such term is used in the Voting Rights Act of 1965 ( 52 U.S.C. 10301 et seq. (b) Masking requirement A State or political subdivision may require that a voter wear a mask in order to enter a polling location only if— (1) the State or political subdivision makes readily available and at no cost to the voter or any individual who accompanies the voter a mask sufficient to comply with any applicable masking requirement; and (2) the State or political subdivision provides reasonable accommodation from such requirement for individuals with a disability as recognized under the Americans with Disabilities Act of 1990 ( 42 U.S.C. 12101 et seq. (c) Definition For purposes of this section, the term vaccination status (1) an individual’s status based on the voluntary election to receive or not to receive a COVID–19 vaccine; and (2) regardless of whether someone has or has not been vaccinated against COVID–19, an individual's status with respect to having or producing proof of such vaccination in the form of a vaccine passport or other medical records that would demonstrate whether an individual has been vaccinated against COVID–19.

Summary: Securing Enfranchisement and the Rights of Voters regardless of Inoculation Status Act or the SERVIS Act This bill prohibits requiring voters to present vaccine passports or other information regarding their COVID-19 vaccination status, and also restricts masking requirements, for voting in federal elections. Specifically, the bill makes it unlawful for any state or political subdivision to require a voter to present a vaccine passport or other information regarding the voter's COVID-19 vaccination status. Further, a state or political subdivision may require a voter to wear a mask in order to enter a polling location only under certain circumstances. In particular, the state or political subdivision must (1) make masks readily available and at no cost to the voter and to an individual who accompanies the voter, and (2) provide reasonable accommodation from such masking requirement to an individual with a disability.
Drug Shortages Shelf Life Extension Act

To require guidance on extending expiration dates for certain drugs, and for other purposes. 1. Short title This Act may be cited as the Drug Shortages Shelf Life Extension Act 2. Extending expiration dates for certain drugs (a) In general Not later than 180 days after the date of enactment of this Act, the Secretary of Health and Human Services (referred to in this section as the Secretary 21 U.S.C. 355 42 U.S.C. 262 (1) the submission of stability testing data in such applications; and (2) establishing in the labeling of drugs the longest feasible expiration date supported by such data, taking into consideration how extended expiration dates may help prevent or mitigate drug shortages. (b) Report Not later than 2 years after the date of enactment of this Act, and again 2 years thereafter, the Secretary shall submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives a report that includes— (1) the number of drugs for which the Secretary has requested the manufacturer make a labeling change regarding the expiration date; and (2) for each drug for which the Secretary has requested a labeling change with respect to the expiration date, information regarding the circumstances of such request, including— (A) the name and dose of such drug; (B) the rationale for the request; (C) whether the drug, at the time of the request, was listed on the drug shortage list under section 506E of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 356e (D) whether the request was made during a public health emergency declared under section 319 of the Public Health Service Act ( 42 U.S.C. 247d (E) whether the manufacturer made the requested change by the requested date, and for instances where the manufacturer does not make the requested change, the manufacturer’s justification for not making the change, if the manufacturer agrees to provide such justification for inclusion in the report.

Summary: Drug Shortages Shelf Life Extension Act This bill requires the Food and Drug Administration (FDA) to issue or revise guidance to address issues relating to extending drug expiration dates. Specifically, the guidance must address recommendations to drug companies relating to (1) submitting stability testing data in applications for market approval for drugs or biological products; and (2) establishing on drug labels the longest feasible expiration date supported by such data, taking into consideration how extended expiration dates may help prevent or mitigate drug shortages. The FDA must also periodically report to Congress certain information about requests to change the expiration date on a drug label, including the number of such requests from the FDA to the manufacturer and the rationale for each request.
Promoting ACCESS to Diagnostics Act

To improve research and development of medical countermeasures for novel pathogens. 1. Short title This Act may be cited as the Promoting Access to Critical Countermeasures by Ensuring Specimen Samples to Diagnostics Act Promoting ACCESS to Diagnostics Act 2. Accessing specimen samples and diagnostic tests (a) Improving research and development of medical countermeasures for novel pathogens (1) Sample access Not later than 1 year after the date of enactment of this Act, the Secretary of Health and Human Services (referred to in this subsection as the Secretary (2) Guidance The Secretary shall issue guidance regarding the procedures for carrying out paragraph (1), including— (A) the method for requesting such samples; (B) considerations for sample availability and use of suitable surrogates or alternatives to such pathogens, as appropriate, including applicable safeguard and security measures; and (C) information required to be provided in order to receive such samples or suitable surrogates or alternatives. (b) Earlier development of diagnostic tests Title III of the Public Health Service Act is amended by inserting after section 319A ( 42 U.S.C. 247d–1 319B. Earlier development of diagnostic tests The Secretary may contract with public and private entities, as appropriate, to increase capacity in the rapid development, validation, manufacture, and dissemination of diagnostic tests, as appropriate, to State, local, and Tribal health departments and other appropriate entities for immediate public health response activities to address emerging infectious diseases that have significant potential to cause a public health emergency. .

Summary: Promoting Access to Critical Countermeasures by Ensuring Specimen Samples to Diagnostics Act or the Promoting ACCESS to Diagnostics Act This bill directs the Department of Health and Human Services (HHS) to support the development of medical products and diagnostic tests for emerging infectious diseases. Specifically, HHS must develop policies and procedures governing access by public and private entities to samples of pathogens (or suitable surrogates). The samples may be used for preparedness and response activities, developing medical products for emerging infectious diseases, and similar purposes. Additionally, HHS may contract with public and private entities to increase the capacity to rapidly develop, validate, and disseminate diagnostic tests to health departments and other entities to respond to emerging infectious diseases with significant potential to cause a public health emergency.
A bill to amend the Post-Katrina Emergency Management Reform Act of 2006 to repeal certain obsolete requirements, and for other purposes.

To amend the Post-Katrina Emergency Management Reform Act of 2006 to repeal certain obsolete requirements, and for other purposes. 1. Repeal of obsolete DHS contracting requirements The Post-Katrina Emergency Management Reform Act of 2006 ( Public Law 109–295 6 U.S.C. 792 May 9, 2022 Reported without amendment

Summary: This act repeals a provision of the Post-Katrina Emergency Management Reform Act of 2006 that requires the Department of Homeland Security to promulgate regulations to minimize the excessive use by contractors of subcontractors or tiers of subcontractors to perform the principal work of any contract for facilitating response to or recovery from a natural or man-made disaster.
Nurse Corps Tax Parity Act of 2022

To amend the Internal Revenue Code of 1986 to exclude certain Nurse Corps payments from gross income. 1. Short title This Act may be cited as the Nurse Corps Tax Parity Act of 2022 2. Tax treatment of certain Nurse Corps payments (a) In general Paragraph (4) of section 108(f) 338B(g) 338B(g) or 846 (b) Qualified scholarships Subparagraph (A) of section 117(c)(2) the Public Health Service Act the Public Health Service Act or the scholarship program under section 846 of such Act (c) Effective date The amendments made by this section shall apply to amounts received in taxable years beginning after the date of the enactment of this Act.

Summary: Nurse Corps Tax Parity Act of 2022 This bill excludes from gross income, for income tax purposes, amounts received by members of the Nurse Corps as scholarships or loan forgiveness.
Restore Parental and Consumer Medical Rights in the Nation's Capital Act

To repeal COVID–19 vaccination requirements imposed by the District of Columbia. 1. Short title This Act may be cited as the Restore Parental and Consumer Medical Rights in the Nation's Capital Act 2. Repeal of DC vaccine mandates The following shall have no force or effect: (1) Order 2021–148 issued by the Mayor of the District of Columbia on December 22, 2021. (2) The Coronavirus Immunization of School Students and Early Childhood Workers Amendment Act of 2021 (D.C. Act 24–285), enacted by the District of Columbia Council on January 12, 2022.

Summary: Restore Parental and Consumer Medical Rights in the Nation's Capital Act This bill nullifies the following actions of the government of the District of Columbia: Order 2021-148 issued by the Mayor on December 22, 2021 (relating to vaccination requirements for entrance into certain indoor establishments and facilities); and the Coronavirus Immunization of School Students and Early Childhood Workers Amendment Act of 2021 (D.C. Act 24-285), enacted by the District of Columbia Council on January 12, 2022.
Francis G. Newlands Memorial Removal Act

To direct the Secretary of the Interior to remove the bronze plaque and concrete block bearing the name of Francis Newlands from the grounds of the memorial fountain located at Chevy Chase Circle in the District of Columbia, and for other purposes. 1. Short title This Act may be cited as the Francis G. Newlands Memorial Removal Act 2. Removal of Plaque and Concrete from Memorial Fountain Grounds (a) In general The Secretary of the Interior shall— (1) remove the brass plaque bearing the name Senator Francis G. Newlands (2) remove from the south end of the memorial fountain’s face, the stone, tablet-like projection bearing the name of Francis Griffith Newlands (3) remove the name Newlands Memorial Fountain (4) offer the items removed pursuant to paragraphs (1), (2), and (3) to the descendants of Francis Griffith Newlands for a period of 60 days, and if not claimed within that period, direct the items removed pursuant to paragraphs (1), (2), and (3) to be maintained by the National Park Service as Federal property and accessioned into the Rock Creek Park museum collection. (b) Memorial fountain For the purposes of this section, the term memorial fountain

Summary: Francis G. Newlands Memorial Removal Act This bill directs the Department of the Interior to (1) remove the brass plaque bearing the name Senator Francis G. Newlands from the grounds of the memorial fountain located at Chevy Chase Circle in the District of Columbia; (2) remove from the south end of the memorial fountain's face, the stone, tablet-like projection bearing the name of Francis Griffith Newlands and a related inscription; (3) remove the name Newlands Memorial Fountain carved into the upper face of the memorial fountain's coping stones; and (4) offer the items removed to the descendants of Francis Griffith Newlands for a 60-day period, and if not claimed within that period, direct the removed items to be maintained by the National Park Service as federal property and accessioned into the Rock Creek Park museum collection.
Increase Access to COVID Testing Act

To require the Secretary of Health and Human Services to provide emergency use authorization with respect to certain COVID–19 diagnostic tests approved for use in the European Union. 1. Short title This Act may be cited as the Increase Access to COVID Testing Act 2. Emergency use approval of certain COVID–19 tests (a) In general For the duration of the public health emergency declared under section 319 of the Public Health Service Act ( 42 U.S.C. 247d 21 U.S.C. 360bbb–3 (b) Tests described An antigen diagnostic test to detect SARS–CoV–2 described in this subsection is such a test— (1) that is included on the common list of COVID–19 rapid antigen tests of the European Commission Directorate-General for Health and Food Safety; and (2) for which the emergency use authorization request is for an at-home, or other non-laboratory site, use, without a prescription. (c) Terms of authorization (1) In general A diagnostic test authorized as described in subsection (a) shall be subject to the same terms and requirements as other products authorized under section 564 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 360bbb–3 (2) Change in status in the EU In the case of an antigen diagnostic test authorized as described in subsection (a), if the European Commission Directorate-General for Health and Food Safety removes such test from the common list described in subsection (b)(1), the Secretary of Health and Human Services, not later than 30 days after such removal from the common list, shall conduct a review of the test to determine whether the emergency use authorization under section 564 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 360bbb–3

Summary: Increase Access to COVID Testing Act This bill directs the Food and Drug Administration (FDA) to provide upon request emergency use authorization for COVID-19 rapid antigen tests approved for use in the European Union. During the declared COVID-19 public health emergency, the FDA shall grant emergency use authorization to a COVID-19 rapid antigen test upon a proper request by the test's manufacturer if (1) the test is on the European Commission Directorate-General for Health and Food Safety's common list for approved COVID-19 tests, and (2) the request is for the non-laboratory use of the test without a prescription. The bill waives certain requirements for a request for emergency use authorization under this bill, such as a finding from the FDA that the test may be effective in diagnosing COVID-19. If a test authorized under this bill is removed from the EU common list, the FDA must determine within 30 days of such removal whether the emergency use authorization for the test should continue.
Red River National Wildlife Refuge Boundary Modification Act

To amend the Red River National Wildlife Refuge Act to modify the boundary of the Red River National Wildlife Refuge, and for other purposes. 1. Short title This Act may be cited as the Red River National Wildlife Refuge Boundary Modification Act 2. Red River National Wildlife Refuge boundary modification Section 3(a)(1) of the Red River National Wildlife Refuge Act ( Public Law 106–300 map entitled Red River National Wildlife Refuge—Selection Area map entitled Red River National Wildlife Refuge Acquisition Boundary

Summary: Red River National Wildlife Refuge Boundary Modification Act This bill modifies the boundary of the Red River National Wildlife Refuge in Louisiana.